Aquinox Pharmaceuticals Inc (AQXP) was Resumed by Leerink Partners to “Outperform” and the brokerage firm has set the Price Target at $24. Leerink Partners advised their investors in a research report released on Oct 4, 2016.
Aquinox Pharmaceuticals Inc closed down -0.26 points or -1.91% at $13.36 with 3,68,214 shares getting traded on Friday. Post opening the session at $13.59, the shares hit an intraday low of $13.35 and an intraday high of $13.82 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Aug 26, 2015, David Chilton Mitchell (VP Global Regulatory & Quality) purchased 3,575 shares at $17.81 per share price. According to the SEC, on Aug 14, 2015, Lloyd Mackenzie (VP Technical Operations) sold 35,887 shares at $18.67 per share price. On Aug 14, 2015, Kamran Alam (CFO, Vice President Finance) sold 29,079 shares at $18.67 per share price, according to the Form-4 filing with the securities and exchange commission.
Aquinox Pharmaceuticals Inc. formerly Aquinox Pharmaceuticals (USA) Inc. is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1 which is a regulator of a cellular signaling pathway in immune cells known as the PI3K pathway. Its lead product candidate AQX-1125 is a small molecule activator of SHIP1 suitable for oral once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125 it is advancing through Phase II development in several initial indications. The Company operates in Vancouver British Columbia Canada.